Steven Lee, PhD   Chief Executive Officer

Dr Lee joined Summit plc as CEO in September 2004. Prior to this, he held a number of senior commercial and business development roles with major UK biotechnology companies including British Biotech plc, PA Consulting Group, Chiroscience Group plc and Datamonitor plc. From 2001 until 2004, Dr Lee was Executive Director of Life Sciences at the commercialisation specialists IP2IPO Ltd (now IP Group plc). He has also acted as a consultant on product strategy to major pharmaceutical companies including Zeneca, Glaxo Wellcome, Novartis and Johnson & Johnson. Dr Lee holds a PhD in parasite epidemiology from Kings College London.

Richard Storer, DPhil   Chief Scientific Officer

Dr Storer was appointed to the Board of Directors as Chief Scientific Officer in May 2006. During his 30-year career within the pharmaceutical industry, he has overseen the progression of several discovery programmes into clinical development with several subsequently being launched to market, including the blockbuster products Epivir and Relenza. His formative years were spent at Glaxo Wellcome before moving to BioChem Pharma Inc (now part of Shire plc) as Senior Director of Chemistry prior to joining Idenix Pharmaceuticals as Senior Vice-President of Chemistry. In 1996 Dr Storer received the Canadian Prix Galien for the discovery of 3TC (Epivir) and is a Fellow of the Royal Society of Chemistry.

Darren Millington, ACMA   Chief Financial Officer & Company Secretary

Mr Millington joined Summit plc in April 2005 as Head of Finance and Company Secretary. He was subsequently appointed to the Board of Directors as Chief Financial Officer in May 2006 and retains his position as the Company Secretary. He is a Chartered Management Account. Having worked in the Audit and Advisory Divisions at Arthur Andersen (later acquired by Deloitte & Touche), he joined IP2IPO Ltd (now IP Group plc) as Group Financial Controller. Mr Millington holds a Masters degree in Theoretical Physics from the University of London.